The company remains a pre-revenue entity with operating losses expanding from $31.0 million in 2023Q4 to $89.6 million in 2026Q1, reflecting the high cost of clinical trial execution.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 1.22M | 3.9M | 0 | 0 | 0 | 0 | 20.03K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -1.22M | -3.9M | 0 | 0 | 0 | 0 | -20.03K |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | 100% | - |
| Operating Expenses | 208.68M | 283.67M | 158.23M | 102.78M | 52.56M | 37.7M | 15.91M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 70.98M | 61.55M | 49.41M | 32.67M | 16.37M | 8.59M | 3.53M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 249.09M | 225.25M | 108.81M | 70.1M | 36.19M | 29.11M | 12.39M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | -2M | -3.14M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -209.89M | -287.57M | -158.23M | -102.78M | -52.56M | -37.7M | -15.93M |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -81.74% | -53.96% | -95.53% | -39.43% | -136.59% | - |
| EBITDA | -207.68M | -283.67M | -157.24M | -102.48M | -52.28M | -37.62M | -15.91M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | -14.44% | -80.41% | -53.43% | -96.01% | -38.96% | -136.43% | - |
| D&A (Non-Cash Add-back) | 2.21M | 3.9M | 992K | 295K | 277K | 72K | 20.03K |
| EBIT | -192.53M | -140.69M | -158.23M | -102.78M | -52.56M | -37.7M | -15.77M |
| Net Interest Income | 41.15M | 35.97M | 36.01M | -11.64K | 1.26M | -122.04K | 168K |
| Interest Income | 41.15M | 35.97M | 36.03M | 13.38M | 1.26M | 122 | 168.29K |
| Interest Expense | 0 | 0 | 0 | 13.39M | 0 | 122.16K | 0 |
| Other Income/Expense | 39.94M | 146.51M | 36.01M | 13.39M | 1.26M | -122K | 168.29K |
| Pretax Income | -169.96M | -140.69M | -122.22M | -89.38M | -51.3M | -37.82M | -15.77M |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 607.57K | 515K | 310K | 236K | 17K | 231K | 138.24K |
| Effective Tax Rate % | -0.36% | -0.37% | -0.25% | -0.26% | -0.03% | -0.61% | -0.88% |
| Net Income | -170.56M | -141.2M | -122.53M | -89.62M | -51.32M | -40.01M | -15.9M |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | -19.01% | -15.24% | -36.72% | -74.63% | -28.28% | -151.57% | - |
| Net Income (Continuing) | -170.56M | -141.2M | -122.53M | -89.62M | -51.32M | -38.05M | -15.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.35 | -2.40 | -2.34 | -2.43 | -1.44 | -1.20 | -0.45 |
| EPS Growth % | -2.33% | -2.56% | 3.7% | -68.75% | -20% | -166.67% | - |
| EPS (Basic) | - | -2.40 | -2.34 | -2.43 | -1.44 | -1.20 | -0.45 |
| Diluted Shares Outstanding | 72.44M | 59.2M | 52.64M | 36.73M | 36.59M | 36.59M | 36.59M |
| Basic Shares Outstanding | 72.44M | 59.2M | 52.64M | 36.73M | 36.59M | 36.59M | 36.59M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Clinical trial execution failure
As reported in financial statements, Structure Therapeutics has seen its quarterly R&D expenditure climb from $20.0 million in late 2023 to $66.7 million by 2026Q1, reflecting the aggressive scaling of clinical trial activities necessary to advance its metabolic pipeline toward pivotal late-stage development milestones.
The consistent upward trajectory in R&D spending suggests a management team prioritizing rapid clinical progression over near-term expense containment. Investors should monitor whether this expenditure level stabilizes as the company transitions from early-stage proof-of-concept to the more capital-intensive Phase 3 trial environment.
Based on the company's reported figures, the 2025Q4 net income of $33.0 million appears to be an outlier driven by non-operating factors rather than core operational profitability, as the firm remains a pre-revenue entity with significant ongoing cash burn associated with its drug discovery platform.
The sudden swing to positive net income in 2025Q4 warrants further investigation, as it likely masks the underlying structural losses inherent in a clinical-stage biotech model. Analysts should focus on the normalized cash burn rate, excluding these non-recurring items, to accurately assess the company's true operational runway.
According to recent SEC filings, the company's operating loss has widened significantly from $31.0 million in 2023Q4 to $89.6 million in 2026Q1, indicating that overhead and clinical costs are currently scaling far more rapidly than any potential future revenue-generating capacity of the current asset portfolio.
The lack of revenue generation means that operating leverage is currently non-existent, leaving the firm entirely dependent on external capital to fund its expanding cost base. This trend suggests that the company is in a high-risk phase where operational efficiency is secondary to the successful clinical validation of its lead metabolic candidate.
As indicated by the quarterly income statement data, the company's reliance on sustained, high-level R&D spending creates a precarious financial profile that may necessitate future dilutive financing if clinical milestones do not yield immediate partnership opportunities or significant value-creating data readouts in the near term.
Short-sellers may focus on the widening gap between cash consumption and the lack of commercial revenue, questioning the long-term viability of the current funding model. The market's valuation of the company appears to hinge on the success of GSBR-1290, leaving little margin for error should clinical data fail to meet the high efficacy bar set by competitors.
Quick answers to the most common questions about buying GPCR stock.
For fiscal year 2025, Structure Therapeutics Inc. (GPCR) reported total revenue of $0.0M.
Structure Therapeutics Inc. (GPCR) reported a net loss of $141.2M for the fiscal year ending 2025.